Human papillomavirus vaccine against cervical cancer: Opportunity and challenge

Cervical cancer is one of the most common cancers threatening women's health, and the persistent infection of high-risk human papillomavirus (HPV) is closely related to the pathogenesis of cervical cancer and many other cancers. The carcinogenesis is a complex process from precancerous lesion t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer letters Ročník 471; s. 88 - 102
Hlavní autoři: Wang, Renjie, Pan, Wei, Jin, Lei, Huang, Weiming, Li, Yuehan, Wu, Di, Gao, Chun, Ma, Ding, Liao, Shujie
Médium: Journal Article
Jazyk:angličtina
Vydáno: Ireland Elsevier B.V 28.02.2020
Elsevier Limited
Témata:
Cancer vaccines
Carcinogenesis
Carcinogens
Cell-mediated immunity
Cervical cancer
Cervix
Chemotherapy
Health risk assessment
Human papillomavirus
Prophylactic vaccine
Radiation therapy
Surgery
Therapeutic vaccine
Vaccines
Womens health
Prophylactic vaccine
Human papillomavirus
Therapeutic vaccine
Cervical cancer
ISSN:0304-3835, 1872-7980, 1872-7980
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Cervical cancer is one of the most common cancers threatening women's health, and the persistent infection of high-risk human papillomavirus (HPV) is closely related to the pathogenesis of cervical cancer and many other cancers. The carcinogenesis is a complex process from precancerous lesion to cancer, which provides an excellent window for clinical prevention, diagnosis, and treatment. However, despite the various preventions and treatments such as HPV screening, prophylactic HPV vaccines, surgery, radiotherapy, and chemotherapy, the disease burden remains heavy worldwide. Currently, three types of prophylactic vaccines, quadrivalent HPV vaccine, bivalent HPV vaccine, and a new nonavalent HPV vaccine, are commercially available. Although these vaccines are effective in protecting against 90% of HPV infection, they provide limited benefits to eliminate pre-existing infections. Therefore, new progress has been made in the development of therapeutic vaccines. Therapeutic vaccines differ from prophylactic vaccines in that they aim to stimulate cell-mediated immunity and kill the infected cells rather than neutralizing antibodies. This review aims at systematically covering the progress, current status and future prospects of various vaccines in development for the prevention and treatment of HPV-associated lesions and cancers and laying foundations for the development of the new original vaccine. •Recent advances in HPV-related cancer biology and the viral action in carcinogenesis.•Development, current status, limitations, and prospects of prophylactic HPV vaccines.•Characteristics of several vaccine platform technologies that are being applied to the therapeutics for HPV diseases.•Research advances and further exploration of HPV vaccines.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0304-3835
1872-7980
1872-7980
DOI:10.1016/j.canlet.2019.11.039